Risk-adapted dosing of melphalan for systemic AL amyloidosis (AL) lowers treatment-related mortality: Early death but not post-3 month survival is linked to cardiac involvement Meeting Abstract


Authors: Comenzo, R. L.; Zhou, P.; Hassoun, H.; Kewalramani, T.; Klimek, V.; Cohen, A. D.; Ferrand, S. K.; Dhodapkar, M.; Feldstein, J. T.; Fleisher, M.; Nimer, S. D.
Abstract Title: Risk-adapted dosing of melphalan for systemic AL amyloidosis (AL) lowers treatment-related mortality: Early death but not post-3 month survival is linked to cardiac involvement
Meeting Title: 47th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 106
Issue: 11 Pt. 1
Meeting Dates: 2005 Dec 10-13
Meeting Location: Atlanta, GA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2005-11-01
Start Page: 337A
Language: English
ACCESSION: WOS:000233426002091
PROVIDER: wos
PUBMED: 16342400
Notes: --- - Meeting Abstract: 1156 - 47th Annual Meeting of the American-Society-of-Hematology - DEC 10-13, 2005 - Atlanta, GA - Part 1 - "Source: Wos"
MSK Authors
  1. Virginia Klimek
    107 Klimek
  2. Julie T Feldstein
    288 Feldstein
  3. Adam D Cohen
    42 Cohen
  4. Raymond L Comenzo
    112 Comenzo
  5. Ping Zhou
    43 Zhou
  6. Hani Hassoun
    146 Hassoun
  7. Stephen D Nimer
    339 Nimer
  8. Martin Fleisher
    236 Fleisher
Related MSK Work